



(12) Translation of
European patent specification

(11) NO/EP 3190128 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 16/42 (2006.01)
A61K 39/395 (2006.01)
A61P 37/08 (2006.01)

Norwegian Industrial Property Office

(21) Translation Published 2019.04.08

(80) Date of The European Patent Office Publication of the Granted Patent 2018.11.14

(86) European Application Nr. 16170993.6

(86) European Filing Date 2009.09.17

(87) The European Application's Publication Date 2017.07.12

(30) Priority 2008.09.17, US, 97819 P

(84) Designated Contracting States: AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; SE ; SI ; SK ; SM ; TR

(62) Divided application EP2853545, med inndato 2009.09.17

(73) Proprietor Xencor, Inc., 111 W. Lemon Avenue, Monrovia, CA 91016, USA

(72) Inventor DESJARLAIS, John R., 1030 North Michigan Avenue, Pasadena, CA 91104, USA
CHU, Seung Y., 4613 Larwin Ave, Cypress, CA 90630, USA
HORTON, Holly M., 46 Parker Street, Acton, MA 01720, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **COMPOSITIONS AND METHODS FOR TREATING IGE-MEDIATED DISORDERS**

(56) References Cited: WO-A2-2004/065417, CHU SEUNG Y ET AL: "Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, vol. 45, no. 15, 1 September 2008 (2008-09-01), pages 3926-3933, XP002498116, ISSN: 0161-5890, DOI: 10.1016/J.MOLIMM.2008.06.027 [retrieved on 2008-08-08], US-A- 6 037 453

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Antistoff for anvendelse i behandlingen av allergisk astma i et subjekt med behov for samme, hvilket antistoff omfatter:

- a. en tung kjede med SEQ ID NO:42; og
- 5 b. en lett kjede med SEQ ID NO:40.